[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adolescent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adolescent":33},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,47,74,102,121,147,177,200,228,250,298,325,354,381,413,438,476,507,535,562,586,618,646,680,705],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641432","reducing-disparities-in-knee-arthroscopy-for-adolescents-100641432",false,"NCT07580625","Reducing Disparities in Knee Arthroscopy for Adolescents","RED KARD: Reducing Disparities in Knee Arthroscopy for Adolescents","RED KARD","Inclusion Criteria:\n\n* Predominantly Hispanic soccer team\n* Players between 14-18 years of age\n\nExclusion Criteria:\n\n-Players younger than 14 or older than 18 years of age","ALL","14 Years","18 Years",{"count":22,"type":23},80,"ESTIMATED","INTERVENTIONAL",[26],"NA","Hundreds of thousands of youth athletes require surgery for knee injuries annually. The incidence of operative knee injuries has skyrocketed, but surgery can be delayed due to late recognition and barriers, such as insurance, language, and difficulty navigating the healthcare system. Delays may have lifelong effects, including arthritis, persistent instability, poor patient reported outcomes, and reoperation. There is little patient-centered research on barriers to orthopaedic care, and none on interventions to reduce disparities in pediatric sports medicine. This study will focus on Hispanic children, a growing population nationally and 38% of the Chicago's children, who are at increased risk of delayed knee surgery and its sequelae compared to white, non-Hispanic patients. The overall objectives are to identify barriers to timely knee surgery in Hispanic athletes and develop an intervention to implement evidence on expedient treatment. The aim of this study is to evaluate feasibility, acceptability, and appropriateness of a culturally-tailored intervention in a pilot study of Hispanic youth soccer leagues. The proposed study will drive creation of a future community trial of a culturally-tailored intervention.",[29,30,31,32,33],"Knee Injury","ACL Injury","Meniscus Tear","Hispanic or Latino","Adolescent","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":23},"2027-10-01",{"date":42,"type":23},"2029-07",{"name":44,"class":45},"Ann & Robert H Lurie Children's Hospital of Chicago","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100635563","analysis-of-factors-associated-with-delayed-medical-consultation-for-testicular-torsion-among-adolescents-in-the-haut-rhin-department-between-2020-and-2025-100635563","NCT07554313","Analysis of Factors Associated With Delayed Medical Consultation for Testicular Torsion Among Adolescents in the Haut-Rhin Department Between 2020 and 2025","Analyse Des Facteurs de Retard à la Consultation Dans Les Torsions Testiculaires Chez Les Adolescents du Haut-Rhin Entre 2020 et 2025","TORSADO","Inclusion Criteria:\n\n* Patients who underwent surgery for suspected testicular torsion between 2020 and 2025 in the Paediatric Surgery Department of the Hôpitaux Civils de Colmar, following admission via the Paediatric A\\&E Department of the same hospital;\n* Patients aged between 10 and 17 years at the time of admission;\n* Participants who, after being informed, do not object to the use of their data for the purposes of this research;\n* Holders of parental authority who, after being informed, do not object to the use of their children's data for the purposes of this research.\n\nExclusion Criteria:\n\n* Any intraoperative diagnosis other than testicular torsion (e.g. hydatid torsion);\n* Patients who cannot read and\u002For understand French;\n* Participants or legal guardians who have expressed their refusal to take part in the study;\n* Unusable patient records: insufficient data.","MALE","10 Years","17 Years",{"count":59,"type":23},150,"OBSERVATIONAL","The objective of this observational study is to identify the factors that influence whether or not an adolescent seeks immediate medical attention upon the onset of symptoms of testicular torsion. The main question it aims to answer is as follows:\n\nWhat factors are associated with a delay in seeking medical care-defined as a time interval of 6 hours or more between the onset of symptoms and the first visit to Colmar Hospital-among adolescents aged 10 to 18 who underwent surgery for testicular torsion?\n\nParticipation in this study involves completing a questionnaire: the \"Questionnaire for Assessing Factors Associated with Delay in Seeking Medical Care for Testicular Torsion in Adolescents.\"",[63,33],"Testicular Torsion","RECRUITING","2026-05-18",{"date":67,"type":38},"2026-05-20",{"date":69,"type":38},"2026-05-13",{"date":71,"type":23},"2026-12-31",{"name":73,"class":45},"Centre Hospitalier de Colmar",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100596318","phase-2-romiplostim-n01-for-chemotherapy-induced-thrombocytopenia-in-pediatric-cancer-patients-100596318","NCT07043894","Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients","A Prospective, Multicenter Study on the Efficacy and Safety of Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia (CIT) in Children, Adolescents, and Young Adults (CAYA) With Hematological and Solid Tumors","Inclusion Criteria:\n\n1. Voluntary participation with signed informed consent.\n2. Aged 6-24 years, any gender.\n3. ECOG performance status 0-2.\n4. Histologically\u002Fcytologically confirmed non-myeloid malignancy requiring high-intensity chemotherapy with ≥1 myelosuppressive agent.\n5. Patients with potential curative opportunity eligible for standard therapy.\n6. Chemotherapy-induced thrombocytopenia (platelets \\\u003C75×10⁹\u002FL).\n7. Anticipated survival ≥8 months.\n8. Planned ≥2 additional chemotherapy cycles (21-\u002F28-day cycles).\n9. Laboratory parameters meeting:\n\n   * Renal function: Cr ≤1.5×ULN; Ccr ≥55 mL\u002Fmin.\n   * Hepatic function:\n\n     * Total bilirubin ≤1.5×ULN; ALT\u002FAST ≤3×ULN;\n     * For liver metastasis\u002Fcholangiocarcinoma: bilirubin ≤3×ULN, transaminases ≤5×ULN.\n10. No participation in other drug trials within 4 weeks.\n11. Good compliance with efficacy\u002Fsafety follow-up per protocol.\n12. Absence of severe complications (e.g., active GI bleeding\u002Fperforation, jaundice, obstruction, non-cancer fever \\>38°C).\n13. Ability to comprehend and sign informed consent.\n\nExclusion Criteria:\n\n1. Hematologic disorders (non-CIT etiology): AML, ITP, MDS, MPN, multiple myeloma, etc.\n2. Non-CIT thrombocytopenia within 6 months (e.g., chronic liver disease, hypersplenism, infection, hemorrhage).\n3. Known hypersensitivity to romiplostim N01 or excipients (cellulose-lactose, L-HPC, magnesium stearate, film coating).\n4. Refractory cytopenias:\n\n   * Hemoglobin \\\u003C50 g\u002FL despite RBC\u002FEPO;\n   * ANC \\\u003C1.0×10⁹\u002FL despite G-CSF.\n5. Pelvic\u002Fspinal\u002Flarge-field radiotherapy within 3 months.\n6. Arterial\u002Fvenous thrombosis within 3 months.\n7. Severe cardiovascular disease (NYHA Class III-IV, arrhythmia with thromboembolic risk, post-CABG\u002Fstent) within 6 months.\n8. Use of rhTPO, rhIL-11, or TPO-RAs (eltrombopag\u002Favatrombopag\u002Fhetrombopag) within 2 weeks.\n9. Investigator-assessed risks compromising safety\u002Fefficacy evaluation.","6 Years","24 Years",{"count":84,"type":23},50,[86],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents\u002Fyoung adults (CAYA; aged 6-24 years) with hematologic malignancies or solid tumors. The main questions it aims to answer are:\n\n* What proportion of participants achieve platelet count recovery (≥100×10⁹\u002FL or an increase of ≥30×10⁹\u002FL from baseline) within 3 weeks of romiplostim N01 treatment?\n* What is the safety profile of romiplostim N01 in this population, including the incidence and severity of adverse events (especially bleeding and thrombosis)? This is a single-arm study (no comparison group). Researchers will assess the outcomes against predefined efficacy thresholds and historical data (e.g., a 60.7% response rate reported for another TPO-RA, hetrombopag).\n\nParticipants will:\n\n* Receive weekly subcutaneous injections of romiplostim N01 (starting dose: 2 µg\u002Fkg).\n* Have their romiplostim dose adjusted weekly based on platelet counts (increase by 1-2 µg\u002Fkg if platelets \\\u003C99×10⁹\u002FL, maximum dose 10 µg\u002Fkg, stop when target recovery is met).\n* Undergo frequent monitoring, including blood tests (especially platelet counts), vital signs, physical exams, and assessment for adverse events and bleeding throughout the treatment and follow-up period.",[89,90,91,33,92],"Solid Tumors","Hematological Tumor","Children","Chemotherapy Induced Thrombocytopenia","2026-05-06",{"date":95,"type":38},"2026-05-07",{"date":97,"type":38},"2025-12-25",{"date":99,"type":23},"2026-09-01",{"name":101,"class":45},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":81,"maxAge":82,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":46},"100587312","phase-2-telpegfilgrastim-vs-filgrastim-for-secondary-prevention-of-chemotherapy-induced-neutropenia-in-pediatric-solid-tumors-100587312","NCT06926751","Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","A Multicenter, Randomized, Controlled Study of Telpegfilgrastim Versus Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Children and Adolescents With Solid Tumors Receiving High-Intensity Chemotherapy Regimens","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed malignant solid tumor requiring high-intensity chemotherapy, with ≥2 remaining chemotherapy cycles, and either:\n\n   * Previous febrile neutropenia(FN) or dose-limiting neutropenia in the prior chemotherapy cycle without prophylactic granulocyte colony-stimulating factor (G-CSF);\n   * Previous FN or dose-limiting neutropenia in the prior chemotherapy cycle despite prophylactic G-CSF.\n2. Age ≥6 to ≤24 years.\n3. Eastern Cooperative Oncology Group Performance Status ≤1.\n4. Normal bone marrow hematopoietic function: hemoglobin ≥75 g\u002FL, white blood cell count ≥3.0×10\\^9\u002FL, platelets ≥80×10\\^9\u002FL, and neutrophils ≥1.5×10\\^9\u002FL.\n5. Anticipated survival ≥8 months.\n6. Willing to participate, with written informed consent signed by the patient or legal guardian.\n\nExclusion Criteria:\n\n1. Bone marrow involvement at screening.\n2. Uncontrolled localized or systemic infection.\n3. Known hypersensitivity to Telpegfilgrastim, recombinant human granulocyte-colony stimulating factor(rhG-CSF), or other pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) agents.\n4. Concurrent participation in any other investigational drug or device trial.\n5. Severe organ dysfunction: total bilirubin, alanine aminotransferase(ALT), or aspartate transaminase(AST) \\>2.5 × upper limit of normal(ULN) (or \\>5 × ULN in patients with liver metastases), serum creatinine \\>5 × ULN.\n6. Severe psychiatric disorders affecting informed consent provision or adverse event assessment.\n7. Any condition deemed by the investigator to compromise patient safety or interfere with study outcomes, including risks from the investigational product or confounding adverse event evaluation.",{"count":110,"type":23},132,[86],"The goal of this clinical trial is to evaluate the efficacy and safety of Telpegfilgrastim (a PEGylated recombinant human granulocyte colony-stimulating factor, PEG-rhG-CSF) compared to Filgrastim (short-acting rhG-CSF) in preventing chemotherapy-induced neutropenia (CIN) in children and adolescents aged 6-24 years with malignant solid tumors receiving high-intensity chemotherapy regimens. The main questions it aims to answer are:\n\n* Does Tuopefilgrastim reduce the incidence of febrile neutropenia (FN) in the first chemotherapy cycle (Cx+1) compared to Filgrastim?\n* How do the two treatments compare in terms of duration and severity of neutropenia, chemotherapy delays\u002Fdose reductions, antibiotic use, and bone pain incidence? Researchers will compare the Telpegfilgrastim group (3:1 ratio, 99 participants) with the Filgrastim group (33 participants) to determine if Telpegfilgrastim demonstrates superior efficacy and safety.\n\nParticipants will:\n\n* Receive subcutaneous injections of either Telpegfilgrastim (33 μg\u002Fkg, single dose) or Filgrastim (5 μg\u002Fkg\u002Fday, multiple doses) 24 hours after each chemotherapy cycle.\n* Undergo blood tests, physical exams, and temperature monitoring during follow-up visits.\n* Be assessed for bone pain severity using age-appropriate scales (FLACC or Wong-Baker).\n* Complete two chemotherapy cycles with close safety and efficacy monitoring.",[89,91,33,114],"Chemotherapy Induced Neutropenia",{"date":95,"type":38},{"date":117,"type":38},"2025-06-12",{"date":119,"type":23},"2027-09-01",{"name":101,"class":45},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":20,"enrollmentInfo":130,"targetDuration":132,"studyType":60,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":46},"100626064","parent-adolescent-relationships-emotional-regulation-and-hrv-in-adolescents-with-depression-100626064","NCT07430774","Parent-Adolescent Relationships, Emotional Regulation, and HRV in Adolescents With Depression","CONNECT Study: Parent-Adolescent Relationships, Emotional Regulation, and HRV in Adolescents With Depression","CONNECT","Inclusion Criteria:\n\n1. Aged 12-18 years at the time of screening.\n2. Current Major Depressive Disorder (MDD) documented in the electronic medical record by a licensed clinician; diagnosis verified using the Mental Health History - Parent Form.\n3. Lives with a parent\u002Flegal guardian at least 50% of the time, confirmed on the Demographics Form.\n4. Able and willing to provide assent, with a parent\u002Flegal guardian able and willing to provide informed consent.\n5. Willingness to comply with all study procedures, including wearing a Fitbit Charge 5 for 7 nights, syncing the device through a compatible smartphone, and completing all required assessments (DERS-36, PHQ-9, anthropometrics, Youth Activity Profile, caffeine logs, PACHIQ-R).\n6. Primary caregiver willing to participate, including completion of the PACHIQ-R (Caregiver).\n7. If taking antidepressant medication, must be on a stable dose for at least 4 weeks before screening, verified on the Self-Administered Comorbidity Questionnaire.\n8. English-speaking adolescent and caregiver, as all measures used in the study are validated in English.\n9. Available for two in-person study visits within the study period.\n\nExclusion Criteria\n\n1. Medical conditions affecting autonomic function or HRV (arrhythmia, congenital heart disease, cardiomyopathy, Type 1 or Type 2 diabetes, thyroid disorders, or moderate-to-severe sleep apnea), as reported on the Self-Administered Comorbidity Questionnaire.\n2. Use of medications known to affect heart rate or HRV, including beta-blockers, calcium channel blockers, antiarrhythmics, tricyclic antidepressants, stimulants, or antipsychotics, as documented on the NIMH Concomitant Medication Log.\n3. Active substance use, including nicotine\u002Ftobacco, alcohol, marijuana, recreational drugs, or energy drinks, as assessed by the Drug Use Screening Inventory.\n4. Habitual high caffeine intake (\\>200 mg\u002Fday, equivalent to \\>4 cups of coffee or \\>2 cans of caffeinated soda per day), as assessed by a caffeine screening question during eligibility screening.\n5. Psychotic disorders or active psychotic symptoms, as reported on the Mental Health History Questionnaire (Parent) and the Self-Administered Comorbidity Questionnaire.\n6. Acute suicidal ideation requiring immediate intervention, defined as endorsement of agree and strongly agree on items 14-16 of the Concise Health Risk Tracking Self-Report (CHRT-SR), indicating active suicide risk.\n7. Severe cognitive or intellectual impairment interfering with study participation, determined during eligibility screening based on parent report on the Mental Health History Questionnaire and observed inability to complete screening or consent procedures.\n8. Current eating disorder diagnosis (anorexia nervosa, bulimia nervosa, or binge eating disorder), as reported on the Mental Health History Questionnaire.\n9. Concurrent participation in another study involving wearable devices or daily monitoring, as reported on the Eligibility Screening Form.\n10. Skin conditions or sensitivities prevent continuous wear of a wrist-worn device reported on the Eligibility Screening Form.","12 Years",{"count":131,"type":23},74,"1 Week","This cross-sectional study examines associations among heart rate variability (HRV), emotional dysregulation, and parent-adolescent relationship quality in adolescents with Major Depressive Disorder (MDD). We hypothesize that lower HRV will be linked to greater emotional dysregulation and that more supportive parent-adolescent relationships will correlate with higher HRV. Participants will wear a Fitbit Charge 5 during nighttime sleep for 7 consecutive nights and complete validated measures of emotional regulation and relationship quality.",[135,136,33,137,138],"Emotional Dysregulation","HRV","Family Relationship","Depression","2026-04-29",{"date":93,"type":38},{"date":142,"type":23},"2026-07-01",{"date":144,"type":23},"2027-05-01",{"name":146,"class":45},"University of Texas Southwestern Medical Center",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":155,"targetDuration":4,"studyType":24,"phases":157,"briefSummary":159,"conditions":160,"keywords":164,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100624098","phase-4-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-adolescents-with-early-stages-of-chronic-kidney-disease-100624098","NCT07405216","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease","Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Persistent Albuminuria: A Randomized Controlled Clinical Trial","IECA-MEX","Inclusion Criteria:Age 14-18 years\n\nResidence in Aguascalientes\n\nPersistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg)\n\nEstimated glomerular filtration rate ≥60 mL\u002Fmin\u002F1.73 m²\n\nNo identifiable secondary cause (e.g., lupus, diabetes mellitus)\n\nRenal biopsy showing adaptive podocytopathy or perihilar focal segmental glomerulosclerosis -\n\nExclusion Criteria:\n\nHypoalbuminemia\n\nNephrotic syndrome\n\nPersistent macroalbuminuria (ACR \\>300 mg\u002Fg)\n\nSecondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -",{"count":156,"type":23},200,[158],"PHASE4","Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.\n\nSodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated nephroprotective effects in adult populations with CKD, including reductions in albuminuria and slowing of disease progression, independent of diabetes status. However, no randomized controlled trials have evaluated the efficacy and safety of SGLT2 inhibitors in adolescents with early-stage CKD and persistent albuminuria.\n\nThis randomized, double-blind, placebo-controlled clinical trial aims to evaluate whether treatment with an SGLT2 inhibitor reduces albuminuria in adolescents aged 14 to 18 years with persistent microalbuminuria (albumin-to-creatinine ratio 30-300 mg\u002Fg) and preserved kidney function. Participants will be randomized in a 2:1 ratio to receive dapagliflozin 10 mg daily or placebo for six months. The primary outcome is the change in urinary albumin-to-creatinine ratio from baseline to six months. Secondary outcomes include changes in estimated glomerular filtration rate and safety outcomes.",[161,162,33,163],"Chronic Kidney Disease (Mild to Moderate)","Albuminuria","Sodium Glucose Co-Transporter 2 Inhibitors",[165,166,167],"Chronic kidney disease","Persistent albuminuria","sodium glucose co-transporter 2 inhibitors","2026-04-22",{"date":170,"type":38},"2026-04-27",{"date":172,"type":38},"2026-04-23",{"date":174,"type":23},"2027-10-30",{"name":176,"class":45},"Centenario Hospital Miguel Hidalgo",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":18,"minAge":184,"maxAge":20,"enrollmentInfo":185,"targetDuration":4,"studyType":24,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":46},"100406843","phase-4-pecs-study-for-cied-implantation-surgery-100406843","NCT04577690","PECS Study for CIED Implantation Surgery","Pectoral Nerve (PECS) Block for Cardiac Implantable Electronic Devices (CIED) Implantation Surgery","Inclusion Criteria:\n\n• All patients 3-18 years undergoing CIED surgery in the chest\n\nExclusion Criteria:\n\n* Children \\\u003C 3 years of age at time of procedure as bupivacaine is not licensed for this age group.\n* No parental or patient consent\n* Allergy to bupivacaine\n* Pregnancy or lactation\n* Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.","3 Years",{"count":186,"type":23},48,[158],"We aim to determine whether pectoral nerve block (PECS) performed after induction of anesthesia but before surgical incision results less opioid use in the post operative period compared with local infiltration alone in children undergoing Cardiac Implantable Electronic Device (CIED) surgery.",[190,191,33],"Pain, Postoperative","Child","2026-04-21",{"date":172,"type":38},{"date":195,"type":38},"2019-12-01",{"date":197,"type":23},"2028-01-01",{"name":199,"class":45},"The Hospital for Sick Children",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":209,"targetDuration":4,"studyType":24,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100634992","the-effects-of-throwers-ten-exercises-performed-with-an-external-focus-100634992","NCT07546890","The Effects of Thrower's Ten Exercises Performed With an External Focus","The Effects of Thrower's Ten Exercises Performed With an External Focus on Functional Performance, Balance, and Shooting Performance in Adolescent Basketball Players","The Effects of","Inclusion Criteria:\n\n* Adolescent male basketball players aged 10-18 years\n* With at least one year of continuous participation in basketball\n* Basketball players who participate in regular training at least two days per week\n\nExclusion Criteria:\n\n* Participants will be excluded if they have a history of upper or lower extremity surgery within the past six months\n* do not regularly attend training sessions\n* do not consent to participate",true,{"count":210,"type":23},30,[26],"The aim of this study is to comprehensively investigate the effects of the Thrower's Ten exercise program-commonly recommended to enhance shoulder stability and strength in athletes-when applied using an external focus of attention approach (i.e., directing attention toward an object or movement outside the body), on functional performance, shoulder stability, balance, and throwing performance in adolescent basketball players.\n\nThis study has been designed to examine the effects of performing the Thrower's Ten exercises with an external focus of attention on functional performance, shoulder stability, balance, and throwing performance in adolescent basketball players. Athletes will be randomly assigned to two groups: the experimental group will perform the exercises using an external focus of attention, whereas the control group will perform the same exercises without any specific attentional focus.\n\nThe methods employed in this study are expected to effectively address the research objectives. The data collection tools and analytical techniques to be used are based on validated and widely accepted tests in the literature. Functional performance will be assessed using the Closed Kinetic Chain Upper Extremity Stability Test, balance will be evaluated using the Upper Extremity Y Balance Test, and throwing performance will be measured using the Medicine Ball Throw Test.",[214,215,33],"External Focus (e.g., Performing the Exercise by Directing the Individual's Attention to a Laser Beam)","Exercise Training",[217,218,219],"basketball","throwers ten exercise","functional performance","2026-04-20",{"date":172,"type":38},{"date":223,"type":23},"2026-04-25",{"date":225,"type":23},"2026-07-20",{"name":227,"class":45},"Hacettepe University",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":208,"sex":18,"minAge":129,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":24,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":46},"100493532","an-evidence-based-family-support-program-for-parents-and-children-in-palestine-a-theory-based-intervention-100493532","NCT05706376","An Evidence-based Family Support Program for Parents and Children in Palestine: A Theory-based Intervention","Inclusion Criteria:\n\n* a willing adolescent between the ages of 13 and 16\n* assuming a two-parent family, a mother and father willing to participate\n* within the service area of implementing organizations\n\nExclusion Criteria:\n\n* Families with individuals with significant mental or physical impairments precluding their ability to participate in groups","75 Years",{"count":236,"type":23},900,[26],"Few evidence-based programs exist to support children and families affected by sociopolitical conflict, despite documented evidence of their heightened risk for emotional and behavioral adjustment problems associated with exposure to conflict and violence at multiple levels of the social ecology (e.g., political, community, and family). Thus, a critical need exists for an evidence-based program to ameliorate the impact of political violence on the overall well-being of children and families. The current study will conduct a rigorous evaluation of a theoretically-driven, family-based intervention program in Palestine, including both the West Bank and Gaza. Firmly grounded in the cultural context of Palestine but with broad implications for individuals exposed to sociopolitical violence, the long-term goal of this project is to provide a family-focused intervention program (Promoting Positive Family Futures; PPFF) that may facilitate individuals' sense of safety and support in the context of chronic adversity. The objective is to evaluate this intervention program in the context of a randomized clinical trial (RCT) in the West Bank and Gaza (N=300). The central hypothesis is that the program will have direct positive effects on family conflict, parent psychopathology and parental security in the family as well as on adolescent emotional security in the family, with cascading effects on adolescent adjustment. Consistent with family systems theory, we further hypothesize that treatment effects on parents will mediate on the effects of the treatment on adolescent adjustment. The rationale is that bolstering resilience in family systems is a key approach to promoting positive functioning in families exposed to chronic violence. The hypothesis will be evaluated with three specific aims: 1) evaluate the efficacy of an evidence-based family support program; 2) examine process models of treatment change, and 3) examine interrelations between parent and child functioning. To achieve these aims, the study will be an RCT employing a longitudinal design (N=300) with multi-method assessments at baseline (T1), post-test (T2), 6-month follow-up (T3) and 12-month follow-up (T4). Families included in the study will be evenly divided between the West Bank (n=150) and Gaza Strip (n=150). Families will be randomized into the intervention condition (PPFF) or treatment as usual (TAU). Each territory will have an implementing partner, and implementing partners and investigators will work together to ensure the study procedures are implemented in parallel across sites. Data collection will be conducted by trained research staff from a third-party survey and policy research organization. The proposal seeks to shift current research and clinical paradigms in these contexts by employing novel theoretical concepts, approaches, and methodologies. The contribution will be significant by 1) further developing new directions for empirically-based interventions in these high-risk contexts, and 2) advancing a relatively brief, cost-effective program that can be readily implemented to help children and families exposed to continuing conflict in Palestine, with the potential to be brought to scale in other contexts.",[33,240,241,242],"Psychopathology","Parent-Child Relations","Violence",{"date":172,"type":38},{"date":245,"type":38},"2023-09-19",{"date":247,"type":23},"2027-07-31",{"name":249,"class":45},"University of Notre Dame",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":184,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":46},"100634199","time-to-healing-in-displaced-pediatric-diaphyseal-forearm-fractures-treated-with-bioabsorbable-compared-to-titanium-intramedullary-nails-100634199","NCT07536581","Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails","Time to Healing in Displaced Pediatric Diaphyseal Forearm Fractures Treated With Bioabsorbable Compared to Titanium Intramedullary Nails: A Single-Center, Multi-Blinded, Randomized Parallel-Group, Non-Inferiority Study","FOREST","Inclusion Criteria:\n\n* Diagnosis of a traumatic diaphyseal forearm fracture of the radius, ulna, or both\n* Operative fixation required\n* Fractures must be complete (not unicortical or greenstick) AND displaced \\>50% of bone width (after attempted closed reduction) AND\u002FOR angulated \\>10° in any plane (after attempted closed reduction)\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Conditions where internal fixation is contraindicated (e.g. active or potential infection)\n* Grossly open fractures (Gustilo Anderson grade \\> 2)\n* Fracture occurred more than 2 weeks prior\n* Fractures that are well managed conservatively (undisplaced or minimally displaced)\n* Previous ipsilateral forearm fracture (risk of closed medullary canal)\n* Fractures unsuited for intramedullary nailing (e.g. multifragmentary, metaphyseal or epiphyseal)\n* Concurrent ipsilateral wrist or elbow involvement (e.g. Monteggia or Galeazzi variants)\n* Unable to participate in follow-up\n* Existing bone pathology (e.g. tumor, osteogenesis imperfecta, degenerative disease)\n* Participation in any other medical device or medicinal product study within the previous month that could influence in opinion of the PI the results of the present study\n\nIntraoperative exclusion criteria:\n\n* Fractures suitable for closed reduction and casting (see 6.3.9)\n* Indication for treatment 1 (BIN) only\n* Indication for treatment 2 (ESIN) only\n* Intraoperative decision to use implants other than the devices under investigation","13 Years",{"count":260,"type":23},60,[26],"This study looks at children with forearm fractures that need surgery. The standard treatment uses titanium nails, which usually need to be removed in a second operation later. This study compares titanium nails with bioabsorbable nails, which gradually dissolve in the body and may help some children avoid another operation.\n\nThe study will compare how quickly the fractures heal on X-ray, and also look at complications, recovery, function, and the family's experience. Children who need surgery will be randomly assigned to one of the two treatments so the comparison is fair.\n\nHypothesis: The researchers expect that fractures treated with bioabsorbable nails will heal almost as quickly as fractures treated with titanium nails, while reducing the need for later implant removal surgery.",[264,265,266,267,191,33,268,269,270,271,272,273,274],"Forearm Injuries","Radius Fractures","Ulna Fractures","Fractures, Bone","Fracture Fixation, Intramedullary","Internal Fixation","Orthopedic Operations","Polymers","Fracture Healing","Radiography","Randomized Controlled Trial (RCT)",[274,276,277,278,279,280,281,282,283,284,285,286,287,288,289],"pediatric forearm fracture","forearm shaft fracture in children","elastic stable intramedullary nailingelastic stable intramedullary nailing","ESIN","titanium elastic nail","bioabsorbable intramedullary nail","TEN","BIN","radiographic healing","radiographic union","modified Radiographic Union Score","mRUS","non-inferiority trial","randomized trial","2026-04-17",{"date":168,"type":38},{"date":293,"type":23},"2026-04",{"date":295,"type":23},"2031-12",{"name":297,"class":45},"Children's Fractures Interest Group, Denmark",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":57,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":324},"100621371","enhancing-brain-and-mental-health-through-breathing-practice-100621371","NCT07369752","Enhancing Brain And Mental Health Through Breathing Practice","Enhancing Brain And Mental Health Through Breathing Practice: Clinical Applications In Rural Adolescents With Psychiatric Symptoms (Breathing Study -Adolescent)","Inclusion Criteria:\n\n* Adolescents between the ages of 12 and 17 who have been diagnosed with a major depressive disorder (mild or moderate) and\u002For an anxiety disorder.\n* Participants may have co-occurring mild to moderate alcohol or drug use problems, provided these do not require immediate specialized treatment or crisis intervention.\n* All participants must be receiving care at one of two participating MCHS outpatient psychiatry clinics and may reside in rural area (RUCA code 4-10) or non-rural area.\n* Participants must be able to read and understand English, and both parental or guardian consent and adolescent assent will be required.\n\nExclusion Criteria:\n\n* Current suicidal ideation or self-harm behavior requiring immediate clinical intervention\n* Presence of severe psychiatric comorbidities such as psychosis, bipolar disorder, depression with psychotic features, severe alcohol and drug use, or eating disorders.\n* Participants with significant cognitive impairment that would interfere with study participation.",{"count":306,"type":23},40,[26],"The purpose of this study is to evaluate the feasibility of a structured breathing intervention in rural and non-rural adolescents diagnosed with anxiety and depression, recruited from outpatient pediatric and child\u002Fadolescent psychiatry clinics.",[310,311,33],"Depressive Disorder","Anxiety",[313,314],"Seokmun Hoheup","breathing","2026-04-02",{"date":317,"type":38},"2026-04-03",{"date":319,"type":38},"2026-02-19",{"date":321,"type":23},"2027-01",{"name":323,"class":45},"Mayo Clinic",2,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":46},"100625427","suicidal-behavior-in-adolescents-and-executive-functions-100625427","NCT07422493","Suicidal Behavior in Adolescents and Executive Functions","SAFE","Inclusion Criteria:\n\n* Adolescents aged 11 to 16 years (inclusive), hospitalized at Angers University Hospital in the Child or Adolescent Surgery and Medicine units for the management of suicidal behaviors (suicide attempts and\u002For suicidal ideation)\n* Covered by the national health insurance system\n* Assent of the adolescent\n* Written informed consent provided by the legal guardians to participate in the study\n\nExclusion Criteria:\n\n* Complete inability to complete the questionnaires (Non-communicative patient; Severe comprehension or communication disorders, Limited or no understanding of the French language)\n* Participation in another interventional study that modifies clinical care\n* Presence of a neurological condition likely to significantly impair cognitive functioning (e.g., epilepsy, brain tumor, neurometabolic disease)\n* Previous inclusion in this study during an earlier hospitalization","11 Years","16 Years",{"count":335,"type":23},100,[26],"Suicide is a major public health concern, particularly among young people. In France, around 400 adolescents die by suicide every year, and suicide attempts are most frequent during adolescence. This stage of life is marked by profound emotional, social, and biological changes, which can increase vulnerability to stress and psychological distress.\n\nCurrent research shows that suicidal behaviors do not result from a single cause. Instead, they emerge from a complex interaction between individual vulnerabilities and stressful life events. Among these vulnerabilities, cognitive functioning-and more specifically executive functions-has attracted growing scientific interest.\n\nExecutive functions refer to a set of high-level mental abilities that allow individuals to regulate their thoughts, emotions, and actions. They include skills such as controlling impulses, adapting to new situations, planning ahead, and holding information in mind. These abilities are essential for everyday life, school learning, social interactions, and emotional regulation. Importantly, the brain networks supporting executive functions continue to develop throughout adolescence, making them particularly sensitive to psychological and environmental challenges.\n\nIn adults, several studies have shown that people with suicidal ideation or a history of suicide attempts often present difficulties in executive functioning. Such difficulties may contribute to poorer emotional regulation, increased rumination, reduced impulse control, and impaired decision-making during periods of crisis. However, in adolescents, research in this area remains limited, often involving small samples or focusing on only one or two cognitive abilities.\n\nThe main aim of this study is therefore to better understand the relationship between executive functions and suicidal behaviors in adolescents, using a comprehensive assessment tool specifically designed and validated for children and teenagers. This tool allows for a global evaluation of key executive components, including inhibition, working memory, cognitive flexibility, and planning.\n\nA secondary objective of the study is to compare executive functioning between adolescents who experience suicidal thoughts and those who have attempted suicide. Some findings in adults suggest that these two groups may show different cognitive profiles, but this distinction has rarely been explored in younger populations.\n\nIn addition, cognitive difficulties may not only appear during testing but also have a real-life impact, affecting academic performance, emotional regulation, and social relationships. For this reason, the study also examines how executive difficulties affect everyday functioning, by collecting information from adolescents themselves, their parents, and the school environment.\n\nFinally, suicidal behaviors in adolescents are influenced by many other factors, particularly psychiatric disorders such as depression, anxiety, and the consequences of traumatic experiences. Depression, in particular, is one of the strongest risk factors for suicide. This study therefore also aims to explore how these psychiatric conditions may influence executive functioning and shape the relationship between cognitive difficulties and suicidal behavior.\n\nBy improving our understanding of these mechanisms, this research seeks to support the development of more effective prevention strategies and better-targeted clinical interventions for adolescents at risk.",[339,33],"Suicidal Behavior",[341,342,343],"adolescent","Executive functions","suicide","2026-04-01",{"date":346,"type":38},"2026-04-07",{"date":348,"type":23},"2026-05",{"date":350,"type":23},"2027-10",{"name":352,"class":353},"University Hospital, Angers","OTHER_GOV",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":362,"maxAge":363,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":380},"100516090","phase-2-a-master-protocol-ly900023-that-includes-several-clinical-trials-of-drugs-for-children-and-young-adults-with-cancer-100516090","NCT05999994","A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research","CAMPFIRE","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll.\n\n* Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).\n* The participant has a Lansky (\\\u003C16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.\n* Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects.\n* The participant has adequate hematologic and organ function.\n* Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.\n* Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.\n\nParticipants will be ineligible if they meet any of the exclusion criteria below. Additional criteria are specified in the protocol amendment to which the participant will enroll.\n\n* Participants with severe and\u002For uncontrolled concurrent medical disease or psychiatric illness\u002Fsocial situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.\n* Participants who have active infections requiring therapy.\n* Participants who have had allogeneic bone marrow or solid organ transplant.\n* Participants who have had, or are planning to have, certain invasive procedures.\n* Female participants who are pregnant or breastfeeding.","1 Year","39 Years",{"count":365,"type":23},105,[86],"The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug\u002Fdisease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.",[369,191,33],"Neoplasms","2026-03-26",{"date":372,"type":38},"2026-03-27",{"date":374,"type":38},"2020-01-22",{"date":376,"type":23},"2027-05",{"name":378,"class":379},"Eli Lilly and Company","INDUSTRY",73,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":24,"phases":392,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years","35 Years",{"count":391,"type":23},96,[86,393],"PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[396,191,33,397,398,399,400,401,402],"Classical Hodgkin Lymphoma","Young Adult","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan","2026-03-17",{"date":405,"type":38},"2026-03-19",{"date":407,"type":38},"2024-09-25",{"date":409,"type":23},"2039-11-15",{"name":411,"class":412},"Children's Cancer Group, China","NETWORK",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":208,"sex":18,"minAge":184,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":46},"100535288","pediatric-normative-markerless-movement-analysis-100535288","NCT06249880","Pediatric Normative Markerless Movement Analysis","Pediatric Normative Markerless Movement Analysis Data Collection Project","Inclusion Criteria:\n\n* Age: 3-25 years of age (with 3 and 25 year olds considered for inclusion).\n* Ambulate independently and without the use of assistive devices or orthoses.\n* Willing and interested in participating.\n\nExclusion Criteria:\n\n* Neuromuscular disorders such as cerebral palsy, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, peripheral neuropathy, or other generalized muscle and\u002For nerve issues.\n* Evidence of developmental delays, muscle weakness, decreased muscle tone, joint stiffness, muscle or bone deformity.\n* Currently using or has a history of using assistive technology devices, bracing\u002Forthoses, manual or powered mobility equipment.\n* History of premature birth.\n* Currently or has a history of taking medication or pharmaceutical treatment related to musculoskeletal side-effects\u002Fscenario\u002Fdiagnosis.","25 Years",{"count":306,"type":23},"The objective of this project is to collect baseline data from a normative population of 20 children that gender and age matches the population of patients expected to be treated by Mary Bridge Children's Research \\& Movement Lab.",[424,33],"Pediatric ALL",[426,427,428],"Motion Analysis","Kinetics","Kinematics","2026-03-05",{"date":431,"type":38},"2026-03-09",{"date":433,"type":38},"2024-03-01",{"date":435,"type":23},"2028-12",{"name":437,"class":45},"MultiCare Health System Research Institute",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":208,"sex":446,"minAge":129,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":464,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":46},"100628155","effectiveness-of-an-mhealth-innovation-on-the-impact-of-menstrual-complaints-in-adolescents-100628155","NCT07457957","Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents","The Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents - A Randomised Controlled Trial","MGA","Inclusion Criteria:\n\n* Dutch, English, Turkish or Moroccan-Arabic speaking\n* Post menarche\n* Access to a smartphone or tablet with iOS or Android operating system\n\nExclusion Criteria:\n\n* Amenorrhea\n* Pregnancy\n* No menstrual bleeding or withdrawel bleeding in the 3 months prior to inclusion.\n* Previously or currently under treatment by a health care provider for menstrual complaints","FEMALE","21 Years",{"count":449,"type":23},874,[26],"The aim of this study is to improve menstrual health-related quality of life in adolescents by using a mobile menstrual health tracker. We will perform a randomized controlled trial to evaluate the (cost)-effectiveness of this mHealth intervention.",[453,454,455,456,457,458,459,460,461,462,463,33],"Dysmenorrhea","Heavy Menstrual Bleeding","Menstrual Cramps","Menstrual Bleeding, Heavy","Menstrual Discomfort","Menstrual Cycle Abnormal","Menstrual Disorder","Menstrual Health","Mobile Application","mHealth","Menstrual Health Intervention",[465,462,466,33,467],"randomized clinical trial","Menstrual health","Menstrual Tracker App","2026-03-04",{"date":431,"type":38},{"date":471,"type":23},"2026-02-16",{"date":473,"type":23},"2029-05-31",{"name":475,"class":45},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":492,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":46},"100541054","start-now-adapted-culturally-adapted-version-of-start-now-100541054","NCT06324864","START NOW Adapted: Culturally Adapted Version of START NOW","Testing the Effectiveness of the Culturally Adapted Skills Training START NOW to Reduce Mental Health Problems in Adolescent Refugees","Inclusion Criteria:\n\n* Being a migrant resettled in Switzerland temporarily or permanently\n* Aged between 14 and 18\n* Able to speak, read and understand one of the following languages: German, English, Turkish, Farsi, Dari, Ukrainian, Algerian Arabic or Pashto\n* Able to give informed consent as documented by signature\n* At least sub-clinical depressive symptoms assessed by the Hopkins Symptom Checklist-25 (HSCL-25); total score \\> 1.75, OR\n* Having elevated levels of psychological distress assessed by Kessler Psychological Distress Scale (K10); total score \\> 20\n\nExclusion Criteria:\n\n* Suicidality assessed in self-report by the Suicide Behaviors Questionnaire-Revised (SBQ-R; total score \\> 6) and external report by telephone clarification\n* Planning to leave Switzerland in the next 6 months\n* Concurrent CBT-based skills-training similar to START NOW",{"count":22,"type":23},[26],"The goal of this clinical trial is to test the effectiveness of the culturally adapted skills-training START NOW in youth migrant populations. The main question it aims to answer is: Is the culturally adapted skills training START NOW more effective than treatment as usual (TAU) in reducing mental health problems in migrants? Participants will be randomly assigned to the intervention group receiving the skills training START NOW Adapted or the control group receiving TAU. Researchers will compare both groups to see if START NOW Adapted is more effective than TAU in reducing mental health problems in migrants.",[138,487,311,33,488,489,490,491],"Depression\u002FAnxiety","Emotion Recognition","Mental Health","Resilience,Psychological","Refugee Health",[493,494,495,496,497,498],"randomized controlled trial","effectiveness trial","refugee health","cultural adaptation","skills-training","adolescent migrants","2026-02-17",{"date":319,"type":38},{"date":502,"type":38},"2024-03-13",{"date":504,"type":23},"2026-12",{"name":506,"class":412},"Prof. Christina Stadler",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":20,"enrollmentInfo":513,"targetDuration":4,"studyType":24,"phases":514,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":46},"100613036","the-effect-of-three-dimensional-exercises--schroth-method--on-trunk-muscle-endurance-sleep-quality-and-quality-of-life-in-adolescents-with-hyperkyphosis-100613036","NCT07261358","The Effect of Three-Dimensional Exercises ( Schroth Method ) on Trunk Muscle Endurance, Sleep Quality, and Quality of Life in Adolescents With Hyperkyphosis","Inclusion Criteria:\n\n* Adolescents between 12 and 18 years of age\n* Presence of thoracic kyphosis with a T3-T12 Cobb angle ≥45° measured on a lateral thoracic radiograph\n* Sufficient physical and cognitive ability to actively participate in the exercise protocol for at least 3 months\n* Adequate communication and cognitive capacity to understand the educational materials provided\n* Ability and willingness to regularly complete the exercise log throughout the study period\n\nExclusion Criteria:\n\n* Scoliosis with a Cobb angle \\>10° in the coronal plane\n* Presence of structural spinal deformities such as vertebral fracture, spondylolisthesis\n* History of previous spinal surgery\n* Neuromuscular disorders that may affect the spine (e.g., cerebral palsy, muscular dystrophy)\n* Structural or functional pathologies involving the spine, pelvic complex, or shoulder girdle\n* Balance disorders such as vestibular dysfunction, vertigo, or other conditions affecting postural control\n* Inability to comply with the exercise protocol due to intellectual disability, severe behavioral disorders, or significant communication impairments\n* Participation in professional-level sports activities that may influence exercise capacity or musculoskeletal function\n* Presence of serious cardiopulmonary diseases (e.g., congenital heart disease, pulmonary hypertension)",{"count":260,"type":23},[26],"Adolescence is a critical period for spinal growth, and progression of thoracic hyperkyphosis may lead to pain, weak trunk muscles, sleep disturbances, and reduced quality of life. This study aims to investigate the effects of three-dimensional exercise program based on the Schroth Method on trunk muscle endurance, thoracic kyphosis angle, pain, sleep quality and quality of life in adolescents aged 12-18 years with hyperkyphosis.",[517,518,33,519,520],"Spine Deformity","Kyphosis","Sleep Quality","Trunk Muscle Endurance",[522,523,524,525],"postural kyphosis","sleep quality","trunk muscle endurance","adolescent spine deformity","2026-02-08",{"date":528,"type":38},"2026-02-11",{"date":530,"type":38},"2025-10-06",{"date":532,"type":23},"2026-05-01",{"name":534,"class":353},"Gaziosmanpasa Research and Education Hospital",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":57,"enrollmentInfo":542,"targetDuration":4,"studyType":24,"phases":544,"briefSummary":545,"conditions":546,"keywords":549,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":46},"100471789","neural-connectivity-during-therapy-for-adolescent-ptsd-100471789","NCT05423444","Neural Connectivity During Therapy for Adolescent PTSD","Neural Connectivity Before and After Each of the Three Treatment Phases of Trauma-focused Therapy for Adolescent Posttraumatic Stress","Inclusion Criteria:\n\n* ages 12-17 and Tanner stage 2 or above\n* history of interpersonal trauma\n* PTSD symptoms with a rating of '2' or higher on at least one symptom from each of the 4 clusters, using the Clinician-Administered PTSD Scale for Children and Adolescents, and having a duration of at least one month\n\nExclusion Criteria:\n\n* current or past use of psychiatric medications\n* severe suicidal\u002Fhomicidal ideation\n* current hospitalization\n* other current psychotherapy or previous treatment with TF-CBT\n* history of head injury with loss of consciousness for \\>5 minutes\n* IQ\\\u003C85\n* major medical illness\n* MRI contraindications (metal in body; braces on teeth)\n* psychosis, bipolar 1, autism, developmental disorder, panic disorder\n* first-degree family member with diagnosis of psychosis or bipolar I disorder\n* substance dependence within the past 3 months or current drug use that is frequent",{"count":543,"type":23},180,[26],"Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.",[547,33,548],"PTSD","Psychological Trauma",[550,551,552,341],"neuroimaging","psychotherapy","trauma","2026-01-09",{"date":555,"type":38},"2026-01-13",{"date":557,"type":38},"2022-11-29",{"date":559,"type":23},"2027-02-28",{"name":561,"class":45},"The University of Texas Health Science Center at San Antonio",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":258,"maxAge":57,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":324},"100612006","early-phase-1-subanesthetic-esketamine-in-modified-ect-for-severe-depression-in-adolescents-clinical-and-mechanistic-study-100612006","NCT07247968","Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","Clinical and Mechanistic Study of Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression","Inclusion Criteria:\n\n* Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT);\n* Aged 13 to 17 years,regardless of gender;\n* Educational attainment of primary school or higher;\n* Normal hearing and vision,including color perception;\n* Voluntary participation in the study with signed informed consent;\n* American Society of Anesthesiologists(ASA)physical status classification I-II.\n\nExclusion Criteria:\n\n* Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;\n* Inability to complete the assessment scales;\n* History of substance abuse;\n* Received electroconvulsive therapy(ECT)within 6 months prior to the study;\n* Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;\n* Severe allergy or contraindication to propofol or succinylcholine;\n* Comorbid with other psychiatric disorders.",{"count":570,"type":23},220,[572],"EARLY_PHASE1","The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.\n\nThe sample size was calculated based on the response rate of patients with depression undergoing electroconvulsive therapy(ECT).According to the results of the pilot study,the efficacy rate of subjects receiving adjunctive esketamine was approximately 78%,while the efficacy rate of those receiving only propofol was 63%.The expected superiority difference in remission rates between the two groups was 15%(one-sided)for the power calculation.Assuming a significance level of α=0.05 and a test power of β=0.2,with a 1:1 ratio of sample sizes between the two groups,the total sample size was calculated to be 198 using the PASS software(PASS 2023).Considering a dropout rate of 10%,a total of 220 subjects were required,with 110 subjects in each group.\n\n1. experimental group The patients were given intravenous injection of 0.25 mg \u002F kg esketamine, 1.5 mg \u002F kg propofol and 1 mg \u002F kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy.\n2. In the control group The patients were given normal saline consistent with esketamine injection volume, 1.5mg\u002Fkg of propofol and 1mg \u002F kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy.\n\nEfficacy evaluation 1. Main efficacy indicators Response rate of depressive symptoms after MECT treatment Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized.\n\nParticipants will:\n\nBe randomly assigned to the esketamine group or the control group, and receive standard MECT treatment.\n\nHave seizure parameters, seizure duration, vital signs, and complications recorded.\n\nComplete psychiatric scale assessments, including HAMD-24, BSS, PANSS, WMS-RC and MoCA.\n\nBe assessed at the following time points: HAMD-24 and BSS after each treatment; PANSS after each treatment course;WMS-RC and MoCA before MECT and after one treatment course.\n\nAll subjects did not discontinue antidepressants before modified electroconvulsive therapy(MECT),and they were fasting for 8 hours and no fluids for 2 hours.Three minutes before MECT,continuous qCON monitoring(Apollo-9000A,Chongqing Xideer Medical Equipment Co.,Ltd.,China)was initiated,while monitoring blood pressure,heart rate,and peripheral capillary oxygen saturation.Preoxygenation was administered for 3 minutes.The qCON monitor uses three electrodes on the forehead to collect raw electroencephalogram(EEG)signals.The qCON monitoring includes the qCON index,qNOX index,burst suppression(BS),and signal quality index(SQI).",[575,576,138,33],"Esketamine","ECT","2026-01-06",{"date":579,"type":38},"2026-01-07",{"date":581,"type":38},"2025-11-25",{"date":583,"type":23},"2026-12-20",{"name":585,"class":45},"Min Su",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":18,"minAge":594,"maxAge":363,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":602,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":324},"100606257","optimizing-the-aya-survivors-coping-and-emotional-needs-toolkit-100606257","NCT07173205","Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit","R00 Full Factorial Trial: Optimizing ASCENT","ASCENT","Inclusion Criteria:\n\n* Age at enrollment (adolescents 15-17, emerging adults 18-25, young adults 26-39)\n* Age at diagnosis (adolescents 12-17, emerging adults 15-25, young adults 15-39)\n* Time since completion of treatment: 1 month to 5 years\n* Language: Fluent in English (spoken and written)\n* Technology: Own smart phone with data plan\n\nExclusion Criteria:\n\n* Mental Health: Current diagnosis of severe or persistent mental illness\n* Suicidality: Severe suicidal ideation (including plan and intent)","15 Years",{"count":596,"type":23},208,[26],"Our team has developed a digital intervention that aims to help adolescent and young adult cancer survivors (AYAs) manage symptoms of depression. This tool includes one psychoeducation component and four components that are based on evidence-based interventions for depression. The goal of this study is to test which component or combination of components meaningfully contribute to improvements in depressive symptoms among AYAs.",[138,600,33,397,601],"Cancer","Adult",[603,604,605,606,607,608,609],"AYA","Adolescent and Young Adult","Cancer Survivorship","Depressive Symptoms","Digital Mental Health","Multiphase Optimization Strategy","Full Factorial Trial","2026-01-05",{"date":579,"type":38},{"date":613,"type":38},"2025-10-25",{"date":615,"type":23},"2027-03",{"name":617,"class":45},"East Carolina University",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":57,"enrollmentInfo":624,"targetDuration":4,"studyType":24,"phases":626,"briefSummary":627,"conditions":628,"keywords":632,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":46},"100561706","evaluating-caregiver-involvement-in-primary-care-based-brief-interventions-for-adolescent-alcohol-use-problems-100561706","NCT06593652","Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems","Inclusion Criteria:\n\n* 12-17 years old;\n* Mild to moderate severity for alcohol use (based on standardized surveys from their primary care provider or clinical indication) or other substance use\n* English language fluency\n\nExclusion Criteria:\n\n* N\u002FA",{"count":625,"type":23},615,[26],"Intervention for mild severity alcohol use among U.S. teens is crucial, as alcohol is the most commonly used substance in this age group, yet few receive the necessary interventions. Primary care, where over 90% of youth regularly visit, is an ideal setting for identifying and addressing mild alcohol use disorder (AUD) through brief interventions like motivational interviewing (MI) and cognitive-behavioral therapy (CBT). However, for teens with mild AUD, a single brief session may not be sufficient, raising questions about the role of caregiver involvement. This study seeks to determine the most effective level of caregiver involvement-no involvement, a single live session, or an online self-paced program-in reducing alcohol use among adolescents with mild AUD in primary care settings. The study also explores the impact of these interventions on other outcomes such as substance use and psychosocial functioning, as well as the factors influencing treatment response. The results will guide the selection and implementation of effective, scalable interventions in primary care to address youth alcohol use disorders.",[629,33,630,631],"Alcohol Use","Mild Alcohol Use Disorder","Mild Substance Use Disorder",[633,634,635,629,636],"Brief Intervention","Teen Intervene","Caregiver Involvement","Substance Use","2025-12-29",{"date":639,"type":38},"2026-01-02",{"date":641,"type":38},"2025-08-19",{"date":643,"type":23},"2028-09",{"name":645,"class":45},"Indiana University",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":654,"maxAge":57,"enrollmentInfo":655,"targetDuration":4,"studyType":24,"phases":657,"briefSummary":658,"conditions":659,"keywords":664,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":679},"100599617","window-prophylaxis-for-pediatric-tuberculosis-prevention-trial-100599617","NCT07086820","Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","Window Prophylaxis for Mycobacterium Tuberculosis Infection Prevention in Child and Adolescent Household Contacts: a Cluster-Randomized Controlled Trial","TB-WIN","Inclusion Criteria:\n\n* Household contacts of patient (index case) with a new diagnosis of microbiologically confirmed pulmonary tuberculosis\n* Age ≥5 to \\\u003C18 years old\n\nExclusion Criteria:\n\n* Suspected active tuberculosis in initial assessment (clinical or radiological)\n* Current pregnancy or breastfeeding\n* Immunocompromised\n* Allergy or contraindication to isoniazid or rifapentine\n* Chronic liver disease or alcohol use disorder\n* History of previous treatment for active or latent tuberculosis infection\n* Previous tuberculin skin test\n* Household contacts of a tuberculosis index patient with a known or suspected drug-resistant M. tuberculosis strain\n* Household contacts or a tuberculosis index patient currently living away from home for more than four weeks\n* Household contacts of a tuberculosis index patient who have already received more than 15 daily doses of antituberculous treatment","5 Years",{"count":656,"type":23},647,[26],"The goal of this cluster-randomized controlled trial is to evaluate the effectiveness of tuberculosis preventive treatment (TPT) administered during the \"window period\" to prevent new Mycobacterium tuberculosis infections in children and adolescents.\n\nThe main question it aims to answer is:\n\nCan immediate TPT reduce the incidence of IGRA conversions in children and adolescents who are household contacts of a newly diagnosed pulmonary tuberculosis patient?\n\nResearchers will compare the incidence of new tuberculosis infections-measured by IGRA conversion at 12 weeks-between participants who receive immediate TPT while still uninfected (baseline IGRA-negative) and those who receive standard care, in which TPT is not offered to IGRA-negative contacts.\n\nParticipants will be:\n\n1. Tested for M. tuberculosis infection using the Interferon-Gamma Release Assay (IGRA), specifically the QuantiFERON-TB Gold Plus, at enrollment and after 12 weeks of follow-up.\n2. Take weekly isoniazid and rifapentine for 12 weeks if:\n\n   1. They are assigned to the intervention arm (regardless of baseline IGRA result), or\n   2. They are in the control arm and test IGRA-positive at baseline.\n\nAdditionally, participants from the control arm who experience an IGRA conversion at 12 weeks (following the primary outcome assessment) will also receive TPT, as per standard of care.",[660,661,91,33,662,663],"Tuberculosis Infection","Household Contacts","Tuberculosis Infection, Latent","Tuberculosis",[665,666,667,668,91,33,669,663,670],"Household contacts","Prophylaxis","Tuberculosis infection","Mycobacterium tuberculosis","Randomized clinical trial","Cluster-randomized trial","2025-12-20",{"date":637,"type":38},{"date":674,"type":38},"2025-10-27",{"date":676,"type":23},"2028-11",{"name":678,"class":45},"Pontificia Universidad Catolica de Chile",13,{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":688,"enrollmentInfo":689,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":691,"conditions":692,"keywords":695,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":46},"100611958","multimodal-phenotyping-in-adolescent-inpatient-depression-an-observational-study-100611958","NCT07247344","Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study","Digital Phenotyping and Multimodal Biomarker Discovery for Major Depressive Episodes in Adolescent Inpatients: A Prospective Cohort Study","MAPS-IO","Inclusion Criteria:\n\n* Between 10 and 20 years of age;\n* Diagnosis of major depressive disorder (MDD) or bipolar disorder (BD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Diagnosis is assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) for participants aged ≥18 years, or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL) for participants aged \\\u003C18 years;\n* Current moderate to severe depressive episode, defined as Hamilton Depression Rating Scale (HAMD) score ≥17;\n* Participants and 1 or 2 parents (patients' age\\\u003C 18 years old) provide informed consent after the detailed description of the study.\n\nExclusion Criteria:\n\n* Prior treatment with repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), electroconvulsive therapy (ECT), or standard psychological therapy within 6 months prior to screening;\n* Comorbidity with other DSM-IV Axis I disorders or personality disorders;\n* Judged clinically to be at serious risk of suicide;\n* Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;\n* Unstable medical conditions, e.g., severe asthma; Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;\n* Mental retardation or autism spectrum disorder;\n* Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants);\n* Current drug or alcohol abuse or dependence;\n* Pregnant or lactating females.","20 Years",{"count":690,"type":23},1000,"This cohort study involves the dynamic collection of clinical information from adolescent patients with major depressive episodes (including both major depressive disorder and bipolar disorder), encompassing serum parameters, physiological-behavioral signals, neuroimaging data, and neuropsychological scales. The study aims to summarize the comprehensive clinical characteristics of this population, identify new risk factors, and establish multivariate predictive models for treatment response, cognitive and emotional impairments. Furthermore, this research will thoroughly investigate the underlying neural mechanisms linking clinical manifestations and neuroimaging features in major depressive episodes.",[33,693,694],"Major Depressive Disorder (MDD","Bipolar Disorder (BD)",[696],"Major Depressive Episode","2025-11-23",{"date":581,"type":38},{"date":700,"type":38},"2025-03-01",{"date":702,"type":23},"2029-03",{"name":704,"class":45},"Jiangsu Province Nanjing Brain Hospital",{"id":706,"slug":707,"hasResults":12,"nctId":708,"briefTitle":709,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":12,"sex":18,"minAge":129,"maxAge":20,"enrollmentInfo":712,"targetDuration":4,"studyType":24,"phases":713,"briefSummary":714,"conditions":715,"keywords":720,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":724,"lastUpdatePostDateStruct":725,"startDateStruct":727,"completionDateStruct":729,"leadSponsor":731,"locationsCount":46},"100611858","hd-tdcs-for-adolescent-bipolar-depression-targeting-s1-100611858","NCT07246044","HD-tDCS for Adolescent Bipolar Depression Targeting S1","High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Targeting the Primary Somatosensory Cortex for Bipolar Depression in Adolescents: A Randomized Double-Blind Controlled Trial","Inclusion Criteria:\n\n* Between 12 and 18 years of age;\n* Participants fulfill the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnostic criteria for bipolar disorder (BD). Participants are assessed by the Structured Clinical Interview for DSM-IV for Axis I Disorders (SCID-I, patients' age ≥18 years old), or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K- SADS-PL, patients' age\\\u003C 18 years old);\n* A current moderate or severe depressive episode defined by HAMD≥17 and Young Mania Rating Scale (YMRS) \\\u003C12;\n* Participants receive a stable psychotropic medication regimen prior to randomization to the trial and are willing to remain on the stable regimen during the HD-tDCS treatment phase;\n* Participants and 1 or 2 parents (patients' age\\\u003C 18 years old) provide informed consent after the detailed description of the study.\n\nExclusion Criteria:\n\n* Prior rTMS or tDCS or electroconvulsive therapy (ECT) treatment or standard psychological therapy within 6 months prior to screening;\n* Comorbidity of other DSM-IV axis I disorders or personality disorders;\n* Judged clinically to be at serious suicidal risk;\n* Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;\n* Unstable medical conditions, e.g., severe asthma;\n* Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;\n* Mental retardation or autism spectrum disorder;\n* Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants);\n* Contraindications to tDCS (e.g., metal in head, history of seizure, EEG test suggesting high risk of seizure, known brain lesion);\n* Current drug\u002Falcohol abuse or dependence;\n* Pregnant or lactating female.",{"count":335,"type":23},[26],"This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. Participants will be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care. Biological data, including neuroimaging, blood biomarkers, voice and facial features, Photoplethysmography (PPG), Electroencephalography (EEG), and behavioral data, will be collected to explore potential predictors of treatment response.",[33,716,717,718,719],"Bipolar Depression","tDCS","Primary Somatosensory Cortex","Bipolar Disorder Depression",[721,341,722,723],"primary somatosensory cortex","bipolar depression","high-definition transcranial direct current stimulation","2025-11-17",{"date":726,"type":38},"2025-11-24",{"date":728,"type":38},"2025-09-16",{"date":730,"type":23},"2027-12-31",{"name":704,"class":45}]